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Abstract 
This position statement has been formulated by oncology nurses from the UK Oncology Nursing Society (UKONS) to provide guidance 
for nurses on safe practice with oral anti-cancer medicines. The ultimate aim is to ensure that patients are not only well informed and 
capable of managing their oral anti-cancer medicines, but also supported safely and effectively while they are receiving these treatments. 
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Background 
The past decade has seen a change in the way many patients 
with cancer are managed. There has been a huge increase in 
the number of oral anti-cancer medicines licensed for the 
treatment of solid and haematological tumours, and this has led 
to a rapid escalation of their use. During 2006–7, for example, 
nearly 24 million doses of oral anti-cancer medicines were used 
in England alone [1]. 
The enthusiastic uptake of oral anti-cancer medicines has been 
driven by the advantages they offer to patients and to the NHS, 
in terms of toxicity management, convenience of delivery and 
cost-effectiveness. Compared with intravenous (IV) cancer 
treatments, oral drugs require fewer NHS resources. Patients 
may not need admission to the ward or day unit for cannulation 
and administration of drugs (unless receiving IV anti-cancer 
medicines in combination with the oral drug). This helps to 
reduce the burden on inpatient beds and on nursing and 
pharmacy staff in already stretched chemotherapy units. 
Furthermore, patients reportedly prefer oral to IV anti-cancer 
medication because of the convenience of self-administering 
treatment at home [2]. 
However, while chemotherapy services recognize standards 
advocating the administration of IV cancer treatments by 
appropriately trained nursing staff (as outlined in the Manual for 
Cancer Services [3]), a recent survey of UK pharmacists 
suggests that procedures for the administration of oral anti-
cancer medicines are less rigorous [4]. This has worrying 
consequences: in January 2008, the National Patient Safety 
Agency (NPSA) issued a rapid response report on the potential 
for fatal outcomes if incorrect doses of oral anti-cancer 
medicines are administered [1,5]. This was in response to three 
deaths and 400 patient safety issues involving oral anti-cancer 
medicines reported between November 2003 and July 2007. 
According to the NPSA, half of the reports concerned the wrong 
dosage, frequency, quantity or duration of oral anti-cancer 
treatment. Of further concern are that patient errors may be 
under-reported [6], and the finding of the National Confidential 
Enquiry into Patient Outcome and Death (NCEPOD) that only 
35% of patients who died within 30 days of receiving systemic 
anti-cancer medicines (oral or IV) were judged to have received 
'good' care [7]. In light of these reports, there is clearly a need 
for improved systems covering the management of patients 
receiving oral therapies. 
Without a structured approach to delivery of oral anti-cancer 
treatments, we cannot be sure patients are regularly and 
adequately assessed and reviewed by appropriately qualified 
healthcare professionals. This may leave patients and carers 
feeling overwhelmed by the responsibility of managing their own 
treatments [2,6]. Patient errors may consequently include 
incorrect dosing or late reporting of treatment-related toxicities. 
The National Chemotherapy Advisory Group (NCAG 2009) [8] 
states that the same governance frameworks and care 
processes used for IV chemotherapy should equally apply to 
oral chemotherapy. The British Oncology Pharmacy Association 
has already published a position statement with the aim of 
improving preparation and dispensing of oral anti-cancer 
medicines [9]. UKONS believes that it is now time to provide 
guidance for nurses. The role of this position statement is 
therefore to outline the specialist knowledge and skills required 
to ensure the safe and competent delivery of oral anti-cancer 
medicines and the appropriate care and monitoring of patients 
receiving these treatments. 
 
Definitions 
The commonly understood definition of oral anti-cancer 
medicines covers all drugs with direct anti-tumour activity, orally 
administered to cancer patients [9]. The definition includes 
traditional cytotoxic drugs as well as targeted therapies (see 
Table 1), but does not include hormonal or anti-hormonal 
agents, such as tamoxifen or anastrozole. Drugs fitting this 
definition are included in the remit of this document. 
 
Principles of safe practice 
In general, the principles of safe practice for administration of 
oral anti-cancer medicines should be the same as those for IV 
treatments, as outlined in the Manual for Cancer Services [3]. 
Since patients are required to manage their own treatments 
away from hospital, additional safe practice procedures are 
needed to ensure that patient education is optimal and patients 
are competent in managing their treatment. 
 
Standards, protocols and guidelines 
Guidelines and protocols are required for oral anti-cancer 
medications [1,3], covering the supply of treatment (e.g. 
procedures for ensuring patients are adequately prepared and 
supported to manage oral therapies, and verifying the patient’s 
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Table 1: Examples of oral anti-cancer medicines [18] 
identity before treatment is dispensed). Providers should also 
ensure those managing patients on oral anti-cancer medications 
have the appropriate specialist skills and knowledge to ensure 
safe administration [3]. 
Training 
Within a clinical chemotherapy service, registered nurses who 
administer anti-cancer medicines should have undertaken 
degree-level cancer-related studies, including one or more 
modules in chemotherapy, and their competence should be 
assessed annually [3]. In relation to oral treatment, the training 
programme should include the following: 
•  knowledge of oral anti-cancer medication protocols, as 
detailed in the network list of approved regimens [3]; 
•  cancer drug administration; 
•  establishing and running nurse-led clinics; 
•  communication skills; 
•  assessment of patients receiving anti-cancer 
medication, which is incorporated into an ongoing 
holistic assessment; 
•  assessment of common anti-cancer medication side 
effects, including myelosuppression, nausea, vomiting, 
stomatitis, diarrhoea, hypertension, lethargy and 
palmar-plantar erythrodysesthaesia; 
•  cancer treatment side effects that constitute a medical 
emergency, for example neutropenic sepsis, 
thrombosis and angina; 
•  health and safety aspects of anti-cancer medication 
administration, including storage, safe handling and 
waste disposal. 
 
Prescribing 
The prescribing policy for oral anti-cancer medicines should be 
the same as for IV anti-cancer medication, as outlined in the 
Manual for Cancer Services [3]. All oral anti-cancer medicines 
should be prescribed only in the context of a written protocol 
and treatment plan [1]. 
Nurse prescribing and treatment initiation 
In line with current health policy, nursing and pharmacy roles 
are being expanded to take on responsibilities that were 
traditionally the role of doctors, such as prescribing. Nurse 
prescribing in oncology enables the patients to get the required 
medication on time and may allow patients to be managed 
nearer to home [10]. It facilitates a holistic approach to patient 
care, and it enables sharing of the prescribing workload in busy 
chemotherapy clinics [7,11]. 
The  Manual for Cancer Services [3] states that oral anti-
cancer treatment should be initiated by a cancer specialist. 
These standards have been adapted in certain networks to 
allow non-medical prescribers to prescribe the first cycle (e.g. 
The Christie NHS Foundation Trust and Southampton 
University Hospitals Trust). Variations in local policy must be 
acknowledged and underpinned by appropriate continuous 
professional development and robust governance 
arrangements. 
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Regardless of whether the prescriber is medical or non-medical, 
it is important that he or she has access to and follows local 
written protocols, including guidance on monitoring and 
treatment of toxicity [1,7]. 
Prescriptions 
Where possible, electronic prescribing systems should be used 
because these have been shown to help standardize protocol-
based prescribing and reduce the risk of errors [8]. If an 
approved and validated electronic prescribing system is 
unavailable [4], all prescriptions of anti-cancer medicines should 
be computer generated, at least when using regimens from the 
agreed list [3]. All of these prescriptions should be checked and 
authorized by an appropriately trained pharmacist [3]. 
Prescription verification procedures 
Nurses are well placed to check patient suitability for oral anti-
cancer medicines, for example by noting whether cognitive 
state, social isolation or presence of severe dysphagia prevents 
administration of anti-cancer medication by this route [7]. It is 
important that label directions are clear and unambiguous and 
that they include, where relevant, the intended period of 
treatment, start and stop dates, any special instructions and 
appropriate information about the need for safe handling [9]. 
When patients are self-administering oral anti-cancer medicines 
in their own home, it is important that they [1]: 
•  are aware of the required monitoring arrangements; 
•  have access to information in the written protocol and 
treatment plan from the hospital where treatment was 
initiated; 
•  have access to advice from an appropriately qualified 
healthcare professional (according to training 
requirements outlined on page 6 of the Manual for 
Cancer Services [3]) with experience in cancer 
treatment in that hospital; 
•  are prescribed and dispensed only sufficient 
medication for that cycle (i.e. until their next scheduled 
assessment). 
Patient education and information 
Equipping patients and carers to manage oral anti-cancer 
medications is vital to patient safety, patient concordance and 
treatment success. Cancer nurses and/or pharmacists with 
specialist anti-cancer medication knowledge can ensure that 
patients receive comprehensive education fit for their needs [9]. 
It is recommended that patient preparation takes place within 
dedicated specialist clinics. All cancer services should therefore 
urgently assess the potential role of nurse-led/pharmacist-led 
clinics in the management of patients prescribed oral anti-
cancer therapies [8,12]. 
 
Pre-treatment consultation 
Unique to oral anti-cancer medicines is the need to educate 
patients on self-administration of anti-cancer medication, 
including the principles of safe handling, storage and disposal, 
according to the chemotherapy services and Control of 
Substances Hazardous to Health Regulations 2002 (as 
amended) [9,13]. The pre-treatment consultation should be 
carried out by an appropriately trained healthcare professional 
(according to training requirements outlined on page 6 of the 
Manual for Cancer Services [3]) to ensure that patients fully 
understand how and when to take their oral anti-cancer 
medicines [9]. 
The pre-treatment consultation should be structured and 
supported by nursing protocols and checklists, such as the 
Multinational Association for Supportive Care in Cancer Oral 
Agent Teaching Tool [14]. The consultation should be tailored to 
the individual patient’s needs, knowledge, perception and 
psychological status to enable them to self-manage their 
treatment. Understanding should be checked before the patient 
is given their oral medication [9]. It is further recommended that 
expected patient response to serious side effects, such as 
neutropenic sepsis, are rehearsed with patients and carers, and 
that key points are reviewed at the end of the consultation to 
ensure optimal management of complications. 
The hospital should provide patients with comprehensive, 
evidence-based written, verbal and pictorial advice giving clear, 
unambiguous instructions about their oral anti-cancer 
medications. Full use should be made of NHS cancer websites 
to provide information for patients and carers to ensure the safe 
use of oral anti-cancer medicines [1]. Patient alert cards [15] 
and scheduling diaries [6] are also useful when assisting 
patients to manage their own treatment. Patients should be 
encouraged to record side effects when they occur and have 
this record with them when they are next assessed. 
Topics for discussion (supported by written information) include 
the following [3,9]: 
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•  the intended oral anti-cancer regimen and treatment 
plan including, doses, route of administration, cycles 
intended, investigations, monitoring procedures, 
management of toxicities and any required supportive 
care measures or medications; [1] 
•  local pathway for treatment and management of 
complications; 
•  when and how to take the tablets correctly (e.g. with or 
before food); 
•  what to do in the event of missed doses; 
•  what to do if patients vomit after taking a dose; 
•  what side effects to expect and what to do about them,  
•  which symptoms can patients manage at home? 
•  at what level of severity should they contact the 
hospital? 
•  how side effects will be managed; 
•  potential consequences of not presenting early with 
symptoms; 
•  why and how to obtain further supplies; 
•  what role their GP/community nurses are expected to 
play in their treatment; 
•  principles of safe handling, storage and disposal of 
medications and delivery devices (e.g. plastic spoons), 
and any implications for family members;. 
•  possible interactions with other drugs, supplements or 
herbal remedies. 
Key information points should be reinforced and holistic patient 
needs explored on subsequent visits [9]. 
 
Consent 
Chemotherapy nurses should be actively involved in the patient 
consent process and may legally take written consent from 
patients prescribed oral therapies if supported by local Trust 
policy. The British Committee for Standards in Haematology 
guidelines [16] have been endorsed by NCEPOD [7] to assist in 
the reduction in mortality rates within 30 days of systemic anti-
cancer chemotherapy; they note that [17] ‘The healthcare 
professional carrying out the procedure is ultimately responsible 
for ensuring the patient is giving valid consent, and it is they
who will be held responsible in law if this is challenged later. 
However, team-work is now the way the National Health Service 
operates and, where written consent is being sought, it may be 
appropriate for several members of the team to participate in 
the process of seeking consent. It is the responsibility of the 
healthcare professional to ensure that when he/she requires a 
colleague to seek consent on his/her behalf he/she is confident 
that the colleague will work within his/her own competence and 
will not agree to perform tasks which exceed that competence’. 
NCEPOD [7] requires the consent process to include a clear 
outline of possible side effects, including those that are 
potentially life threatening. Consequently, standardized consent 
forms will be developed through a national work stream. 
   
Access to 24-hour specialist oncology advice 
Clinical chemotherapy services should provide a 24-hour 
telephone advice service for patients prescribed oral therapies, 
with appropriately trained nursing, medical or pharmacy staff 
handling queries [3]. Patients can use such services to seek 
advice on anti-cancer medication management including side 
effects, and how to obtain help and treatment for them. It is 
important that this information is well presented and consistent 
with other information that the patients are given by the 
healthcare team [7]. 
NCAG recommends that chemotherapy telephone advice lines 
should be supported by dedicated acute oncology services 
(AOS) [8]. These new services will encompass the management 
of patients who develop severe complications following 
chemotherapy, including neutropenic sepsis. Chemotherapy-
trained nurses have essential skills to support AOS’s and 
should actively engage/lead in their development. 
 
Monitoring and follow-up 
Monitoring of patients who have been prescribed oral anti-
cancer medicines is important for safe care because it helps to 
identify toxicities and complications early, allows prompt 
remedial actions and prevents serious complications and 
possible hospitalization [7,8,12]. Monitoring of patients may be 
particularly important for newer oral anti-cancer therapies, with 
novel modes of action as these may have unexpected side 
effects [17]. Nurses should strongly consider establishing 
proactive targeted support services to identify problems before 
they become serious (e.g. using routine telephone monitoring) 
[8,12]. 
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On-treatment assessment 
All patients should be seen by a healthcare professional with 
specialist knowledge before every treatment cycle [9]. For each 
patient, records should be made of the following [3]: 
•  continued ability to manage treatment at home, patient 
and carer needs and referral to other services; 
•  performance status; 
•  toxicity assessment, including grade, duration, 
management and relevance and any change in 
supportive medications; 
•  the results of essential serial investigations applicable 
to that cycle (and before administration within a cycle, 
if applicable); 
•  any dose modifications, and whether they are intended 
to be permanent; 
•  any cycle (or administration) delays. 
After the final cycle of a treatment course, the records for each 
patient should include the following [3]: 
•  whether the course was completed or not; 
•  if the course was not completed or if the planned dose 
was reduced, the reasons for cessation or reduction; 
•  for completed courses of non-adjuvant treatment, a 
reference to the response; 
•  the plans for ongoing review and support. 
 
The role of the primary care team 
The expanding availability of oral anti-cancer medicines means 
that communication with primary care and community health 
practitioners is increasingly important. Primary care nurses and 
GPs are among those who should be given precise and regular 
information on a patient’s treatment, potential side effects and 
drug interactions, where to get advice, where patients should
report to and how they should be managed in the event of 
treatment complications, such as the following [3,7]: 
•  neutropenic sepsis; 
•  nausea and vomiting; 
•  stomatitis, other mucositis; 
•  palmar-plantar erythrodysesthaesia; 
•  diarrhoea; 
•  hypertension; 
•  angina. 
There are increasing opportunities for shared care between 
secondary and primary care providers [8]. While treatment is 
initiated by specialists, follow-up and monitoring may be shared. 
Where shared care is in place, protocols and guidelines should 
be developed with primary care providers. 
Clinical governance 
Cancer service providers should develop robust quality 
improvement systems, to ensure that protocols and policies 
detailed in national guidance are developed, implemented and 
regularly audited [7,8]. Each chemotherapy service should have 
regular morbidity/mortality meetings to review practice and 
policies and procedures in relation to the safety and quality of 
chemotherapy [7]. Audit should include referral processes, for 
example management of treatment-related emergencies and 
key outcomes of treatment [3]. In addition, the cancer service 
provider should regularly review incidents and errors, and 
subsequent reports should be reviewed by the network 
chemotherapy group and local governance forums [8]. 
This position statement will be reviewed by oncology nurses 
from the UK Oncology Nursing Society in 2012, or sooner if 
warranted. 
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